BACKGROUND: Nonsmall cell lung carcinomas (NSCLCs) are associated with very dismal prognoses, and adjuvant chemotherapy, including irinotecan, taxanes, platin, and vinca alkaloid derivatives, offer patients only slight clinical benefits. Part of the chemoresistance of NSCLC results from the expression in NSCLC cells of a very large set of endogenous proteins, which antagonize chemotherapy-mediated attacks on these tumor cells. METHODS: The authors set up an orthotopic model of a human NSCLC by grafting A549 cells into the lungs of nude mice. They tried treating these A549 NSCLC orthotopic xenograft-bearing nude mice on the basis of various chemotherapeutic protocols, including chronic administrations of taxol, oxaliplatin, and irinotecan. A cyclooxygenase-2 (COX-2) inhibitor (NS-398) also was assayed in combination with taxol. The immunohistochemical expression levels of COX-2, prostaglandin E synthetase (PGES), ornithine decarboxylase (ODC), the lung-related resistance protein (LRP), and glutathione-S-transferase-alpha (GST-alpha), GST-mu, and GST-pi were quantitatively determined by means of computer-assisted microscopy in control and drug-treated NSCLC orthotopic xenografts. RESULTS: The orthotopic A549 xenograft model developed in 100% of the grafted mice, leading to brain metastases in approximately 61% mice and to liver metastases in approximately 40% of mice. The model was resistant to taxol and oxaliplatin and was only weakly sensitive to irinotecan. High levels of chemoresistant markers (i.e., COX-2, PGES, ODC, LRP, GST-alpha, GST-mu, and GST-pi) were observed in the nontreated A549 xenografts, although with dramatic variations in individual expression. Taxol and oxaliplatin significantly increased the levels of expression of COX-2, PGES, GST-mu, and GST-pi in a number of different experimental protocols. CONCLUSIONS: The A549 orthotopic xenograft model could be used to evaluate investigational chemotherapeutic agents to identify drugs rapidly that are more active than the drugs currently in use in hospitals.
BACKGROUND:Nonsmall cell lung carcinomas (NSCLCs) are associated with very dismal prognoses, and adjuvant chemotherapy, including irinotecan, taxanes, platin, and vinca alkaloid derivatives, offer patients only slight clinical benefits. Part of the chemoresistance of NSCLC results from the expression in NSCLC cells of a very large set of endogenous proteins, which antagonize chemotherapy-mediated attacks on these tumor cells. METHODS: The authors set up an orthotopic model of a humanNSCLC by grafting A549 cells into the lungs of nude mice. They tried treating these A549 NSCLC orthotopic xenograft-bearing nude mice on the basis of various chemotherapeutic protocols, including chronic administrations of taxol, oxaliplatin, and irinotecan. A cyclooxygenase-2 (COX-2) inhibitor (NS-398) also was assayed in combination with taxol. The immunohistochemical expression levels of COX-2, prostaglandin E synthetase (PGES), ornithine decarboxylase (ODC), the lung-related resistance protein (LRP), and glutathione-S-transferase-alpha (GST-alpha), GST-mu, and GST-pi were quantitatively determined by means of computer-assisted microscopy in control and drug-treated NSCLC orthotopic xenografts. RESULTS: The orthotopic A549 xenograft model developed in 100% of the grafted mice, leading to brain metastases in approximately 61% mice and to liver metastases in approximately 40% of mice. The model was resistant to taxol and oxaliplatin and was only weakly sensitive to irinotecan. High levels of chemoresistant markers (i.e., COX-2, PGES, ODC, LRP, GST-alpha, GST-mu, and GST-pi) were observed in the nontreated A549 xenografts, although with dramatic variations in individual expression. Taxol and oxaliplatin significantly increased the levels of expression of COX-2, PGES, GST-mu, and GST-pi in a number of different experimental protocols. CONCLUSIONS: The A549 orthotopic xenograft model could be used to evaluate investigational chemotherapeutic agents to identify drugs rapidly that are more active than the drugs currently in use in hospitals.
Authors: Ramesh Dasari; Annelise De Carvalho; Derek C Medellin; Kelsey N Middleton; Frédéric Hague; Marie N M Volmar; Liliya V Frolova; Mateus F Rossato; Jorge J De La Chapa; Nicholas F Dybdal-Hargreaves; Akshita Pillai; Véronique Mathieu; Snezna Rogelj; Cara B Gonzales; João B Calixto; Antonio Evidente; Mathieu Gautier; Gnanasekar Munirathinam; Rainer Glass; Patricia Burth; Stephen C Pelly; Willem A L van Otterlo; Robert Kiss; Alexander Kornienko Journal: ChemMedChem Date: 2015-10-05 Impact factor: 3.466
Authors: Nikolai M Evdokimov; Igor V Magedov; Dominic McBrayer; Alexander Kornienko Journal: Bioorg Med Chem Lett Date: 2016-02-08 Impact factor: 2.823
Authors: Tatjana Mijatovic; Véronique Mathieu; Jean-François Gaussin; Nancy De Nève; Fabrice Ribaucour; Eric Van Quaquebeke; Patrick Dumont; Francis Darro; Robert Kiss Journal: Neoplasia Date: 2006-05 Impact factor: 5.715
Authors: April F Eichler; Euiheon Chung; David P Kodack; Jay S Loeffler; Dai Fukumura; Rakesh K Jain Journal: Nat Rev Clin Oncol Date: 2011-04-12 Impact factor: 66.675
Authors: Shannon Puhalla; William Elmquist; David Freyer; Lawrence Kleinberg; Chris Adkins; Paul Lockman; John McGregor; Leslie Muldoon; Gary Nesbit; David Peereboom; Quentin Smith; Sara Walker; Edward Neuwelt Journal: Neuro Oncol Date: 2015-05 Impact factor: 12.300
Authors: Alexander V Aksenov; Alexander N Smirnov; Igor V Magedov; Mary R Reisenauer; Nicolai A Aksenov; Inna V Aksenova; Alexander L Pendleton; Gina Nguyen; Robert K Johnston; Michael Rubin; Annelise De Carvalho; Robert Kiss; Véronique Mathieu; Florence Lefranc; Jaime Correa; David A Cavazos; Andrew J Brenner; Brad A Bryan; Snezna Rogelj; Alexander Kornienko; Liliya V Frolova Journal: J Med Chem Date: 2015-02-20 Impact factor: 7.446
Authors: Maria Letizia Ciavatta; Florence Lefranc; Marianna Carbone; Ernesto Mollo; Margherita Gavagnin; Tania Betancourt; Ramesh Dasari; Alexander Kornienko; Robert Kiss Journal: Med Res Rev Date: 2016-12-07 Impact factor: 12.944
Authors: Sharon J Pitteri; Lellean JeBailey; Vitor M Faça; Jason D Thorpe; Melissa A Silva; Reneé C Ireton; Marc B Horton; Hong Wang; Liese C Pruitt; Qing Zhang; Kuang H Cheng; Nicole Urban; Samir M Hanash; Daniela M Dinulescu Journal: PLoS One Date: 2009-11-19 Impact factor: 3.240